Does the media refer more to PVLA or TGTX?

In the previous week, TG Therapeutics had 9 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for TG Therapeutics and 9 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.92 beat TG Therapeutics' score of 0.37 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PVLA or APGE more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Apogee Therapeutics N/A -32.64% -31.25%

Does the media refer more to PVLA or APGE?

In the previous week, Palvella Therapeutics had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Palvella Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.06 beat Palvella Therapeutics' score of 0.92 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or SYRE more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Spyre Therapeutics N/A -42.88% -27.76%

Does the media favor PVLA or SYRE?

In the previous week, Palvella Therapeutics had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Palvella Therapeutics and 6 mentions for Spyre Therapeutics. Palvella Therapeutics' average media sentiment score of 0.92 beat Spyre Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or PCVX more profitable?

Vaxcyte's return on equity of -32.51% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Vaxcyte N/A -32.51% -29.51%

Does the media refer more to PVLA or PCVX?

In the previous week, Palvella Therapeutics had 5 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Palvella Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.95 beat Palvella Therapeutics' score of 0.92 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or PVLA more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Palvella Therapeutics N/A -56.87% -42.50%

Does the media prefer IMVT or PVLA?

In the previous week, Palvella Therapeutics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Palvella Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.99 beat Palvella Therapeutics' score of 0.92 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palvella Therapeutics (PVLA) Competitors

$157.24 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$156.96 -0.28 (-0.18%)

As of 07/17/2026 07:52 PM Eastern

Compare

PVLA vs. TGTX, APGE, SYRE, PCVX, and IMVT

Should you buy Palvella Therapeutics stock or one of its competitors? MarketBeat compares Palvella Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palvella Therapeutics include TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Spyre Therapeutics (SYRE), Vaxcyte (PCVX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Palvella Therapeutics compare to TG Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

TG Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	52.67	-$41.72M	-$4.17	N/A
TG Therapeutics	$616.29M	13.63	$447.18M	$2.86	19.19

Palvella Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TG Therapeutics has a net margin of 65.95% compared to Palvella Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
TG Therapeutics	65.95%	88.73%	43.44%

In the previous week, TG Therapeutics had 9 more articles in the media than Palvella Therapeutics. MarketBeat recorded 18 mentions for TG Therapeutics and 9 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.92 beat TG Therapeutics' score of 0.37 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics currently has a consensus price target of $199.53, suggesting a potential upside of 26.90%. TG Therapeutics has a consensus price target of $53.33, suggesting a potential downside of 2.80%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Palvella Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

TG Therapeutics beats Palvella Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Apogee Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Palvella Therapeutics had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Palvella Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.06 beat Palvella Therapeutics' score of 0.92 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Apogee Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	52.67	-$41.72M	-$4.17	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Palvella Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Apogee Therapeutics' return on equity of -32.64% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Palvella Therapeutics presently has a consensus price target of $199.53, suggesting a potential upside of 26.90%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 9.51%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Palvella Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

Palvella Therapeutics and Apogee Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market.

In the previous week, Palvella Therapeutics had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Palvella Therapeutics and 6 mentions for Spyre Therapeutics. Palvella Therapeutics' average media sentiment score of 0.92 beat Spyre Therapeutics' score of 0.62 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Palvella Therapeutics presently has a consensus price target of $199.53, suggesting a potential upside of 26.90%. Spyre Therapeutics has a consensus price target of $101.42, suggesting a potential upside of 1.18%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	52.67	-$41.72M	-$4.17	N/A
Spyre Therapeutics	$890K	9,903.62	-$155.20M	-$2.08	N/A

Summary

Palvella Therapeutics beats Spyre Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Vaxcyte?

Palvella Therapeutics (NASDAQ:PVLA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Vaxcyte's return on equity of -32.51% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Vaxcyte	N/A	-32.51%	-29.51%

Palvella Therapeutics has higher revenue and earnings than Vaxcyte. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	52.67	-$41.72M	-$4.17	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palvella Therapeutics has a beta of -0.2, suggesting that its share price is 120% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Palvella Therapeutics currently has a consensus target price of $199.53, suggesting a potential upside of 26.90%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 53.02%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Palvella Therapeutics had 5 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Palvella Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.95 beat Palvella Therapeutics' score of 0.92 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palvella Therapeutics beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Palvella Therapeutics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Palvella Therapeutics and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.99 beat Palvella Therapeutics' score of 0.92 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus target price of $39.70, indicating a potential downside of 1.39%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 26.90%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics has higher revenue and earnings than Immunovant. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Palvella Therapeutics	$42.81M	52.67	-$41.72M	-$4.17	N/A

Palvella Therapeutics' return on equity of -56.87% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Palvella Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.25B	$3.69B	$6.86B	$12.27B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-37.71	21.21	27.25	23.92
Price / Sales	52.67	304.52	584.48	113.62
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	66.63	8.28	10.70	6.18
Net Income	-$41.72M	$23.81M	$3.59B	$331.89M
7 Day Performance	7.68%	-1.34%	-1.00%	-1.22%
1 Month Performance	39.03%	2.68%	1.66%	-1.30%
1 Year Performance	432.84%	45.93%	25.64%	17.74%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	2.8405 of 5 stars	$157.24 flat	$199.53 +26.9%	+432.8%	$2.25B	$42.81M	N/A	N/A	Positive News
TGTX TG Therapeutics	3.065 of 5 stars	$54.93 -2.6%	$53.33 -2.9%	+44.7%	$8.41B	$616.29M	19.21	290
APGE Apogee Therapeutics	1.8971 of 5 stars	$134.08 -0.2%	$121.25 -9.6%	+240.9%	$8.30B	N/A	N/A	91
SYRE Spyre Therapeutics	1.4324 of 5 stars	$94.12 -7.8%	$101.42 +7.8%	+515.3%	$8.28B	N/A	N/A	73	Gap Down
PCVX Vaxcyte	2.7271 of 5 stars	$56.04 -1.2%	$86.00 +53.5%	+55.2%	$8.09B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. TGTX, APGE, SYRE, PCVX, and IMVT

How does Palvella Therapeutics compare to TG Therapeutics?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Summary

How does Palvella Therapeutics compare to Vaxcyte?

Summary

How does Palvella Therapeutics compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. TGTX, APGE, SYRE, PCVX, and IMVT

How does Palvella Therapeutics compare to TG Therapeutics?

Which has better earnings & valuation, PVLA or TGTX?

Which has more volatility & risk, PVLA or TGTX?

Do insiders and institutionals hold more shares of PVLA or TGTX?

Is PVLA or TGTX more profitable?

Does the media refer more to PVLA or TGTX?

Do analysts prefer PVLA or TGTX?

Summary

How does Palvella Therapeutics compare to Apogee Therapeutics?

Does the media refer more to PVLA or APGE?

Do insiders & institutionals hold more shares of PVLA or APGE?

Which has higher valuation and earnings, PVLA or APGE?

Which has more volatility & risk, PVLA or APGE?

Is PVLA or APGE more profitable?

Do analysts rate PVLA or APGE?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Do insiders & institutionals have more ownership in PVLA or SYRE?

Which has more volatility & risk, PVLA or SYRE?

Does the media favor PVLA or SYRE?

Is PVLA or SYRE more profitable?

Do analysts rate PVLA or SYRE?

Which has preferable earnings & valuation, PVLA or SYRE?

Summary

How does Palvella Therapeutics compare to Vaxcyte?

Is PVLA or PCVX more profitable?

Which has stronger valuation and earnings, PVLA or PCVX?

Do insiders & institutionals have more ownership in PVLA or PCVX?

Which has more risk and volatility, PVLA or PCVX?

Do analysts prefer PVLA or PCVX?

Does the media refer more to PVLA or PCVX?

Summary

How does Palvella Therapeutics compare to Immunovant?

Does the media prefer IMVT or PVLA?

Do analysts prefer IMVT or PVLA?

Which has preferable valuation and earnings, IMVT or PVLA?

Is IMVT or PVLA more profitable?

Which has more risk & volatility, IMVT or PVLA?

Do insiders and institutionals believe in IMVT or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools